down arrow

Virios Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92829J1043
USD
6.09
-0.14 (-2.25%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.096.24

52 Week

1.8729.28
Valuation
Technical
Day's Volume

CASH

26.16 k

Shareholding (Mar 2025)

FII

0.48%

Held by 5 FIIs

DII

98.15%

Held by 1 DIIs

Promoter

0.00%

How big is Virios Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Virios Therapeutics, Inc. has a market capitalization of 9.14 million and reported net sales of 0.00 million with a net profit of -21.98 million over the latest four quarters. Shareholder's funds are at -10.12 million, while total assets amount to 101.21 million.

As of Jun 18, Virios Therapeutics, Inc. has a market capitalization of 9.14 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -21.98 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -10.12 million, and the total assets amount to 101.21 million.

Read More

What does Virios Therapeutics, Inc. do?

22-Jun-2025

Virios Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $11 million and a market cap of $9.14 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -132.82%.

Overview: <BR>Virios Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 9.14 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 8.21 <BR>Return on Equity: -132.82% <BR>Price to Book: 1.29<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Virios Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, Virios Therapeutics, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and Bollinger Bands, with a performance of -7.74% over the past month compared to the S&P 500's 2.33%.

As of 18 August 2025, the technical trend for Virios Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including a mildly bearish daily moving average and a mildly bearish monthly Bollinger Band. Although the weekly MACD and KST are mildly bullish, the overall trend is influenced by the bearish signals from the daily moving averages and Dow Theory. In terms of performance, the stock has underperformed the S&P 500 over the past month and year, with a return of -7.74% compared to the S&P 500's 2.33% for the month, and -2.2% versus 17.14% for the year.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.06

stock-summary
Return on Equity

-173.42%

stock-summary
Price to Book

1.37

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.78%
0%
23.78%
6 Months
8.75%
0%
8.75%
1 Year
142.15%
0%
142.15%
2 Years
-57.04%
0%
-57.04%
3 Years
1932.71%
0%
1932.71%
4 Years
-94.94%
0%
-94.94%
5 Years
0%
0%
0.0%

Virios Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Virios Therapeutics, Inc. technically bullish or bearish?

As of 18 August 2025, the technical trend for Virios Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including a mildly bearish daily moving average and a mildly bearish monthly Bollinger Band. Although the weekly MACD and KST are mildly bullish, the overall trend is influenced by the bearish signals from the daily moving averages and Dow Theory. In terms of performance, the stock has underperformed the S&P 500 over the past month and year, with a return of -7.74% compared to the S&P 500's 2.33% for the month, and -2.2% versus 17.14% for the year....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-2.81%
EBIT to Interest (avg)
-8.85
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
8.21
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.59%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.32
EV to EBIT
-4.40
EV to EBITDA
-4.41
EV to Capital Employed
1.03
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-23.51%
ROE (Latest)
-132.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.37%)

Foreign Institutions

Held by 5 Foreign Institutions (0.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -280.00% vs 28.57% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.90",
          "val2": "-1.10",
          "chgp": "-254.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.80",
          "val2": "-1.00",
          "chgp": "-280.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -132.08% vs 56.56% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.20",
          "val2": "-5.40",
          "chgp": "-125.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.30",
          "val2": "-5.30",
          "chgp": "-132.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.90
-1.10
-254.55%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.80
-1.00
-280.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -280.00% vs 28.57% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.20
-5.40
-125.93%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.30
-5.30
-132.08%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -132.08% vs 56.56% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Virios Therapeutics, Inc. stock-summary
stock-summary
Virios Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."